Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Lutathera in ES-SCLC
NCT03325816Phase 2Completed
- Sponsor
- Georgetown University
- Start
- Nov 2017
- Primary completion
- Mar 2019
- Modality
- Peptides, Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate, nivolumab in small cell lung cancer (SCLC), neuroendocrine tumor of the lung, sponsored by Georgetown University. Started Nov 2017; status: completed.
02
Drugs
lutetium Lu 177 dotatatenivolumab
03
Conditions
small cell lung cancer (SCLC)neuroendocrine tumor of the lung
Beyond the preview
Go deeper on NCT03325816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03325816.